Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Published:2015-11-04 Issue:S2 Volume:3 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Gangadhar Tara C,Hamid Omid,Smith David C,Bauer Todd M,Wasser Jeffrey S,Luke Jason J,Balmanoukian Ani S,Kaufman David R,Zhao Yufan,Maleski Janet,Leopold Lance,Gajewski Thomas F

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/2051-1426-3-S2-O7.pdf

Reference1 articles.

1. Gibney GT, et al: European Cancer Congress. 2015, [abstract 511]

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of cyclic sulfamides via one pot alkylation/aza-Michael cascade reaction;Tetrahedron Letters;2024-09

2. Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials;Statistics in Biopharmaceutical Research;2024-08-28

3. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016;Gynecologic Oncology;2024-07

4. Cancer immunotherapy;Medicinal Chemistry of Anticancer Drugs;2023

5. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer;Frontiers in Immunology;2022-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP